Organovo Holdings Inc ONVO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ONVO is a good fit for your portfolio.
News
-
Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease
-
Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)
-
Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering
-
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
Trading Information
- Previous Close Price
- $0.76
- Day Range
- $0.76–0.78
- 52-Week Range
- $0.73–2.05
- Bid/Ask
- $0.75 / $0.78
- Market Cap
- $10.92 Mil
- Volume/Avg
- 500 / 1.0 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 63.72
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 20
- Website
- https://www.organovo.com
Valuation
|
Metric
|
ONVO
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.13 |
Price/Sales | 63.72 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ONVO
|
|---|---|
Quick Ratio | 1.58 |
Current Ratio | 2.12 |
Interest Coverage | — |
Quick Ratio
ONVO
Profitability
|
Metric
|
ONVO
|
|---|---|
Return on Assets (Normalized) | −109.74% |
Return on Equity (Normalized) | −148.74% |
Return on Invested Capital (Normalized) | −129.41% |
Return on Assets
ONVO
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Jcngsrpcfv | Djqm | $644.0 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Cvfqbvj | Ytnjtw | $121.6 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Xjlsljcd | Zrfcrg | $116.5 Bil | |||
| Moderna Inc
MRNA
| Rmtbcmh | Qcks | $44.4 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Bzxmmzgg | Wplzwt | $30.8 Bil | |||
| argenx SE ADR
ARGX
| Dxbqkxqwh | Cgrj | $25.7 Bil | |||
| BioNTech SE ADR
BNTX
| Jwpvslc | Xhwh | $19.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Gjpwzyrl | Pcdjzrc | $15.6 Bil | |||
| United Therapeutics Corp
UTHR
| Rqlwmgb | Lxz | $14.2 Bil | |||
| Incyte Corp
INCY
| Ytsbqrgw | Npwftrx | $12.0 Bil |